Tandem Diabetes Care (TNDM) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a hold rating to a buy rating in a research report released on Monday morning.

Several other research firms have also recently commented on TNDM. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a hold rating to a buy rating and set a $5.75 target price for the company in a research report on Thursday, April 5th. Stifel Nicolaus restated a hold rating and issued a $4.00 target price on shares of Tandem Diabetes Care in a research report on Friday, March 2nd. BidaskClub upgraded shares of Tandem Diabetes Care from a buy rating to a strong-buy rating in a research report on Wednesday, April 11th. Robert W. Baird upgraded shares of Tandem Diabetes Care from a neutral rating to an outperform rating in a research report on Friday, March 23rd. Finally, Cowen upgraded shares of Tandem Diabetes Care from a market perform rating to an outperform rating in a research report on Wednesday, March 28th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $8.32.

Shares of NASDAQ:TNDM opened at $11.69 on Monday. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 6.45. Tandem Diabetes Care has a fifty-two week low of $11.40 and a fifty-two week high of $11.92. The stock has a market cap of $585.29 million, a P/E ratio of -0.91 and a beta of -0.40.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, March 1st. The medical device company reported ($1.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.13). The company had revenue of $40.00 million for the quarter, compared to analyst estimates of $38.41 million. During the same period in the previous year, the company posted ($0.48) earnings per share. The firm’s revenue was up 61.3% on a year-over-year basis. equities analysts expect that Tandem Diabetes Care will post -1.45 earnings per share for the current fiscal year.

In other news, Director Dick Allen bought 25,539 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was purchased at an average price of $3.88 per share, for a total transaction of $99,091.32. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 9.30% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Gabelli Funds LLC acquired a new stake in shares of Tandem Diabetes Care in the 1st quarter worth approximately $102,000. Cetera Advisor Networks LLC acquired a new stake in shares of Tandem Diabetes Care in the 1st quarter worth approximately $117,000. Element Capital Management LLC acquired a new stake in shares of Tandem Diabetes Care in the 1st quarter worth approximately $184,000. A.R.T. Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 284.4% in the 1st quarter. A.R.T. Advisors LLC now owns 38,518 shares of the medical device company’s stock worth $191,000 after acquiring an additional 28,499 shares during the period. Finally, First Mercantile Trust Co. lifted its stake in shares of Tandem Diabetes Care by 1,051.3% in the 1st quarter. First Mercantile Trust Co. now owns 44,866 shares of the medical device company’s stock worth $223,000 after acquiring an additional 40,969 shares during the period. Hedge funds and other institutional investors own 14.75% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company, which designs, develops and commercializes products for people with insulin dependent diabetes. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply